Mariela C. Coccé, Cristina N. Alonso, Jorge Rossi, Maria S. Felice, Myriam R. Gitter, and Marta S. Gallego
Blood Res 2015; 50(1): 55-58Sang-Yong Shin, Chul-Won Jung, Dong-Chull Choi, Byung-Jae Lee, Hee-Jin Kim, and Sun-Hee Kim
Blood Res 2015; 50(1): 58-61Yun Hwa Jung, and Chi Wha Han
Blood Res 2015; 50(1): 6Manavi Dang, Smeeta Gajendra, Shalini Goel, Bhawna Jha, Tushar Sahni, and Ritesh Sachdev
Blood Res 2015; 50(1): 61-62Meet Kumar, Prakas Mandal, Rajib De, Pinaki Mukherjee, Tuphan Kanti Dolai, and Maitryee Bhattyacharyya
Blood Res 2015; 50(1): 63-65Hyo Jung Kim, Sung-Soo Yoon, Hyeon Seok Eom, Kihyun Kim, Jin Seok Kim, Je-Jung Lee, Soo-Mee Bang, Chang-Ki Min, Joon Seong Park, Jae-Hoon Lee, and Korean Multiple Myeloma Working Party
Blood Res 2015; 50(1): 7-18
International consensus recommendations for identifying the optimal lenalidomide starting dose (when used in combination with dexamethasone) in patients with relapsed or refractory multiple myeloma, according to baseline renal function and cytopenia [21]. Each lenalidomide cycle is 21 days out of 28 days. Reproduced with permission from Macmillan Publishers Ltd: Leukemia, copyright 2011.